Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).
CAR T-cell therapy is a type of immunotherapy used to treat some people with lymphoma that has continued to grow despite prior treatment. The treatment involves using a patient's own T cells (a type of white blood cell), genetically modifying them in the laboratory to recognize a protein on cancer cells, and multiplying them. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment. 
Researchers want to find the best dose of LY4052031 to treat people with advanced solid tumors. The people in this study have metastatic solid tumors that came back or keep growing after treatment. In addition, their tumors make a protein called Nectin-4, which plays a role in cancer growth.
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Standard chemoradiation may cause severe side effects such as mouth and gut sores, sore throat, and changes in taste.
Researchers are doing this study to see how well sotorasib gets into metastatic brain tumors. The people in this study have tumors in the brain that have spread there from other parts of the body. They are planning to have the brain metastases removed with surgery. In addition, their tumors have a mutation (change) in the KRAS gene (KRAS G12C+).
The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
